AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis
Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Seladelpar improves wellbeing and lowers itch impact
Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Ongoing seladelpar treatment continues to benefit PBC patients
Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.
Seladelpar cholestasis benefits extend long term
Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.
Real-world data support seladelpar use in PBC patients switching from obeticholic acid
Real-world evidence supports seladelpar use in patients with PBC initiating seladelpar second-line or switching from obeticholic acid.
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
Breaking down PBC: a comprehensive guide
Led by Kris Kowdley, this interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) provides details on the pathogenesis, diagnosis, management and latest clinical data for PBC. Click through the sections, or download the PDF to use as a guide in your clinic.
Breaking down PBC: a comprehensive guide
Interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) providing details on the pathogenesis, diagnosis, management and latest clinical data.
Breaking analysis of ASSURE from EASL 2024
Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
‘Rapid and durable response’ with seladelpar in patients with PBC and cirrhosis
ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.
The evolving landscape of PBC: new therapies and future directions
Kris Kowdley and David Jones share their insights on the evolving landscape of PBC, including new and upcoming therapy options, and how these may change practice for the disease.
The Liver Meeting 2023 – updates to the current landscape
Dr Palak Trivedi joins Dr Gideon Hirschfield to explore pivotal insights from The Liver Meeting 2023. Together, they highlight crucial updates, unveil novel findings, and deliver a concise overview of the current landscape of PBC.
Gideon Hirschfield highlights noteworthy findings on PBC
Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.
Positive RESPONSE for seladelpar in patients with PBC
RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
